|
US6858712B1
(en)
|
1984-08-22 |
2005-02-22 |
The United States Of America As Represented By The Department Of Health And Human Services |
Cloning and expression of HTLV-III DNA
|
|
US6174666B1
(en)
|
1992-03-27 |
2001-01-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of eliminating inhibitory/instability regions from mRNA
|
|
CA2194488A1
(en)
|
1994-08-05 |
1996-02-15 |
Tod Paul Holler |
Method of using transdominant negative retroviral integrase in the treatment of retroviral infection
|
|
US7488485B2
(en)
|
2003-09-16 |
2009-02-10 |
University Of Kansas Medical Center |
DNA vaccine compositions and methods of use
|
|
DE19856463B4
(de)
|
1998-11-26 |
2006-02-02 |
Heinrich-Pette-Institut |
Retrovirale, mit LCMV pseudotypisierte Hybrid-Vektoren
|
|
US7935805B1
(en)
|
1998-12-31 |
2011-05-03 |
Novartis Vaccines & Diagnostics, Inc |
Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
|
|
JP2003523721A
(ja)
|
1998-12-31 |
2003-08-12 |
カイロン コーポレイション |
抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用
|
|
AUPQ776100A0
(en)
|
2000-05-26 |
2000-06-15 |
Australian National University, The |
Synthetic molecules and uses therefor
|
|
CA2458995C
(en)
|
2001-08-31 |
2013-04-30 |
Chiron Corporation |
Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
|
|
US20070077257A1
(en)
|
2001-09-14 |
2007-04-05 |
Emini Emilio A |
Enhanced first generation adenovirus vaccines expressing condon optimized HIV1-Gag, Pol, Nef and modifications
|
|
US7172761B2
(en)
|
2001-11-07 |
2007-02-06 |
Duke University |
Polyvalent immunogen
|
|
AU2002363436A1
(en)
|
2001-11-07 |
2003-05-19 |
Duke University |
Polyvalent immunogen of hiv
|
|
US7195768B2
(en)
|
2001-11-07 |
2007-03-27 |
Duke University |
Polyvalent immunogen
|
|
WO2003053338A2
(en)
|
2001-11-16 |
2003-07-03 |
The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services |
Novel chimeric rev, tat, and nef antigens
|
|
GB0225788D0
(en)
|
2002-11-05 |
2002-12-11 |
Glaxo Group Ltd |
Vaccine
|
|
CA2519025A1
(en)
|
2003-03-28 |
2004-10-07 |
The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services, Centers For Disea |
Immunogenic hiv-1 multi-clade, multivalent constructs and methods of their use
|
|
CN102010463A
(zh)
|
2003-09-17 |
2011-04-13 |
杜克大学 |
共有/祖先免疫原
|
|
US20070275010A1
(en)
|
2003-09-18 |
2007-11-29 |
Mark Feinberg |
Mva Vaccines
|
|
JP2007534302A
(ja)
|
2003-09-24 |
2007-11-29 |
オクソン セラピュティクス リミテッド |
Ｈｉｖ医薬
|
|
GB2406336A
(en)
|
2003-09-24 |
2005-03-30 |
Oxxon Pharmaccines Ltd |
HIV Pharmaccines
|
|
GB0417494D0
(en)
|
2004-08-05 |
2004-09-08 |
Glaxosmithkline Biolog Sa |
Vaccine
|
|
DK1778282T3
(en)
|
2004-08-17 |
2016-06-06 |
Roussy Inst Gustave |
Mutated HIV NEF TO MODULATION OF IMMUNITY
|
|
US8000900B2
(en)
|
2004-09-21 |
2011-08-16 |
Microsoft Corporation |
Association-based predictions of pathogen characteristics
|
|
US8478535B2
(en)
|
2004-10-29 |
2013-07-02 |
Microsoft Corporation |
Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails
|
|
JP5122983B2
(ja)
|
2005-02-24 |
2013-01-16 |
メディカル リサーチ カウンシル |
Ｈｉｖｃｏｎ：ｈｉｖ免疫原及びその使用
|
|
ES2281252B1
(es)
|
2005-07-27 |
2009-02-16 |
Consejo Superior De Investigaciones Cientificas |
Vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapeuticas contra el sida.
|
|
US7951377B2
(en)
|
2005-08-23 |
2011-05-31 |
Los Alamos National Security, Llc |
Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens
|
|
CA2620874A1
(en)
|
2005-08-23 |
2007-03-01 |
The Regents Of The University Of California |
Polyvalent vaccine
|
|
US8119144B2
(en)
|
2006-06-02 |
2012-02-21 |
International Aids Vaccine Initiative |
HIV-1 Clade A consensus sequences, antigens, and transgenes
|
|
KR101999376B1
(ko)
|
2006-07-28 |
2019-07-11 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
개선된 백신 및 이의 사용 방법
|
|
US8452541B2
(en)
|
2007-06-18 |
2013-05-28 |
Microsoft Corporation |
Vaccine design methodology
|
|
US8452542B2
(en)
|
2007-08-07 |
2013-05-28 |
Lawrence Livermore National Security, Llc. |
Structure-sequence based analysis for identification of conserved regions in proteins
|
|
DK2604695T3
(da)
|
2007-12-27 |
2023-01-16 |
Univ Zuerich |
Replikationsdefekte arenavirusvektorer
|
|
ES2699685T3
(es)
|
2008-11-18 |
2019-02-12 |
Beth Israel Deaconess Medical Ct Inc |
Vacunas antivíricas con inmunogenicidad celular mejorada
|
|
US8974788B2
(en)
|
2009-08-14 |
2015-03-10 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
|
EP2552480A1
(en)
|
2010-03-26 |
2013-02-06 |
GlaxoSmithKline Biologicals S.A. |
Hiv vaccine
|
|
US10285942B2
(en)
|
2011-04-07 |
2019-05-14 |
Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health |
Methods of inducing an immune response against HIV by administering immunogenic peptides obtained from protease cleavage sites
|
|
GB201122297D0
(en)
|
2011-12-23 |
2012-02-01 |
Retroscreen Virology Ltd |
Vaccine - screening method
|
|
EP2620446A1
(en)
|
2012-01-27 |
2013-07-31 |
Laboratorios Del Dr. Esteve, S.A. |
Immunogens for HIV vaccination
|
|
US9501614B2
(en)
|
2012-05-22 |
2016-11-22 |
Indiana University Research And Technology Corporation |
Method for computer-aided vaccine discovery
|
|
WO2013188886A2
(en)
|
2012-06-15 |
2013-12-19 |
California Institute Of Technology |
Method and system for parallel batch processing of data sets using gaussian process with batch upper confidence bound
|
|
WO2014026033A1
(en)
|
2012-08-08 |
2014-02-13 |
University Of Florida Research Foundation, Inc. |
Cross-reactive t cell epitopes of hiv, siv, and fiv for vaccines in humans and cats
|
|
WO2014036488A1
(en)
|
2012-08-31 |
2014-03-06 |
Biovest International, Inc. |
Methods for producing high-fidelity autologous idiotype vaccines
|
|
WO2014042669A1
(en)
|
2012-09-12 |
2014-03-20 |
Duke University |
Antibody evolution immunogens
|
|
US9782473B2
(en)
|
2013-03-26 |
2017-10-10 |
Globeimmune, Inc. |
Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
|
|
US9732121B2
(en)
|
2013-09-25 |
2017-08-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Rational vaccine design for hepatitis C virus
|
|
US9855329B2
(en)
|
2013-09-30 |
2018-01-02 |
Los Alamos National Security, Llc |
Mosaic HIV envelope immunogenic polypeptides
|
|
ES2957209T3
(es)
|
2013-09-30 |
2024-01-15 |
Triad Nat Security Llc |
Polipéptidos inmunogénicos mosaicos del VIH de región conservada
|
|
AP2017009846A0
(en)
|
2014-09-26 |
2017-03-31 |
Beth Israel Deaconess Medical Ct Inc |
Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
|
|
MA40783A
(fr)
|
2014-10-03 |
2017-08-08 |
Los Alamos Nat Security Llc |
Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
|
|
ES2811093T3
(es)
|
2014-11-13 |
2021-03-10 |
Univ Geneve |
Arenavirus trisegmentados como vectores de vacunas
|
|
US10421788B2
(en)
|
2015-09-10 |
2019-09-24 |
The General Hospital Corporation |
Synthesizing vaccines, immunogens, and antibodies
|
|
US20180263985A1
(en)
|
2015-09-15 |
2018-09-20 |
Gilead Sciences, Inc. |
Modulators of toll-like receptors for the treatment of hiv
|
|
CA3008641A1
(en)
|
2015-12-16 |
2017-06-22 |
Gritstone Oncology, Inc. |
Neoantigen identification, manufacture, and use
|
|
IL262963B2
(en)
|
2016-05-18 |
2025-01-01 |
Hookipa Biotech Gmbh |
Trisegmented PICHINDE viruses as vaccine vectors
|
|
EP3526236B1
(en)
|
2016-10-17 |
2025-12-10 |
Beth Israel Deaconess Medical Center, Inc. |
Signature-based human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
|
|
IL319407A
(en)
|
2016-11-23 |
2025-05-01 |
Gritstone Bio Inc |
Administration of neoantigens in the virus
|
|
PL3601367T3
(pl)
|
2017-03-30 |
2025-03-31 |
The University Of Queensland |
Cząsteczki chimeryczne i ich zastosowania
|
|
CN110636852A
(zh)
|
2017-04-19 |
2019-12-31 |
磨石肿瘤生物技术公司 |
新抗原的鉴别、制造及使用
|
|
JP2020518648A
(ja)
|
2017-05-08 |
2020-06-25 |
グリットストーン オンコロジー インコーポレイテッド |
アルファウイルス新生抗原ベクター
|
|
EP4512817A3
(en)
|
2017-06-09 |
2025-08-20 |
Seattle Project Corp. |
Neoantigen identification, manufacture, and use
|
|
US20210147550A1
(en)
|
2017-08-18 |
2021-05-20 |
Joshua Michael Francis |
Antigen-binding proteins targeting shared antigens
|
|
CA3073812A1
(en)
|
2017-09-05 |
2019-03-14 |
Gritstone Oncology, Inc. |
Neoantigen identification for t-cell therapy
|
|
WO2019070730A1
(en)
|
2017-10-02 |
2019-04-11 |
Duke University |
MOSAIC ENVELOPES OF HIV-1 TO INDUCE ADCC RESPONSES
|
|
WO2019075112A1
(en)
|
2017-10-10 |
2019-04-18 |
Gritstone Oncology, Inc. |
IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS
|
|
EP3714275A4
(en)
|
2017-11-22 |
2021-10-27 |
Gritstone bio, Inc. |
REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS
|
|
WO2019133853A1
(en)
|
2017-12-28 |
2019-07-04 |
Gritstone Oncology, Inc. |
Antigen-binding proteins targeting shared antigens
|
|
JP2022539417A
(ja)
|
2019-07-02 |
2022-09-08 |
グリットストーン バイオ インコーポレイテッド |
Ｈｉｖ抗原及びｍｈｃ複合体
|
|
JP7454645B2
(ja)
|
2019-07-16 |
2024-03-22 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｈｉｖワクチン並びにその作製方法及び使用方法
|
|
US20220380412A1
(en)
|
2019-10-23 |
2022-12-01 |
Duke University |
Compositions comprising v2 opt hiv envelopes
|
|
WO2022006095A2
(en)
|
2020-06-29 |
2022-01-06 |
Duke University |
Mosaic hiv-1 envelopes to induce adcc responses
|
|
CA3234955A1
(en)
|
2021-10-12 |
2023-04-20 |
Barton F. Haynes |
Compositions comprising v2 opt hiv envelopes
|